Introduction
Acute myelogenous leukemia (AML) is a heterogeneous disorder with diverse genetic abnormalities. The discovery of mutations in the nucleophosmin (NPM1) gene in AML patients, especially those with a normal karyotype, was recently reported by Falini et al.
1 NPM1 mutations result in the dislocation of nucleophosmin from the nucleus to the cytoplasm, and are associated with a higher rate of complete remission after chemotherapy. 1 These findings have later been confirmed by several studies, showing that NPM1 mutations are one of the most frequent genetic abnormalities in adult de novo AML. [1] [2] [3] [4] [5] [6] [7] AML carrying cytoplasmic mutated NPM1 show distinctive biological, pathological and clinical features, 8, 9 including close association with normal karyotype, high incidence of fms-like tyrosine kinase 3 (FLT3)-internal tandem duplications (ITDs), distinct gene expression profiling and good prognosis.
Angiogenesis is controlled by the net balance between positive and negative angioregulatory molecules and is suggested to play a role in leukemogenesis. 10 The angiopoietins constitute a family of growth factors involved in regulation of vascular stability and maturation. The ligand Angiopoietin-1 (Ang-1) stimulates Tie2 receptor autophosphorylation, 11 an action that may be antagonized by the naturally occurring antagonist Ang-2. 12 Ang-1 binding to Tie2 receptor strengthens the interactions between endothelial cells and periendothelial support cells, whereas Ang-2 primarily disrupts Ang-1-mediated receptor activation, resulting in vessel destabilization. However, the final effect of Ang-2 depends on the local angioregulatory cytokine network, either resulting in an angiogenic response or vessel regression. Thus, the Ang/Tie2 system is important in angiogenesis and is possibly important for bone marrow angioregulation in AML. 10 To further investigate the role of the angiopoietin/Tie-2 system in leukemogenesis, we examined the release profile of Ang-1 and Ang-2 from primary AML cells cultured alone and in cocultures with stromal cells. Patients with NPM1 mutations had a slight increase in the expression of Ang-1 mRNA, and NPM1 mutations were also associated with release of Ang-1 protein. However, local Ang-1 levels in the bone marrow are in addition modulated by bone marrow stromal cells and possibly also antagonized by high systemic (serum) levels of Ang-2 in AML patients. Our study is thereby the first to link NPM1 mutations to a specific angioregulatory phenotype.
Materials and methods

AML primary cells
All studies were approved by the regional research ethics committee (Health Region III, Bergen, Norway) and conducted in accordance with the Declaration of Helsinki. Samples were collected after informed consent. During the period 1994-2006 AML cells were consecutively collected from 91 patients (47 females, 44 males; median age 63 years; range 29-89 years). These patients had at least 80% AML cells among circulating leukocytes and the number of circulating blasts was higher than 10 Â 10 9 l À1 . In a previous study we described in detail the clinical and biological characteristics of patients collected according to these criteria, during the period 1991-2001. 13 Our overall patient population and the various patient subsets in this present study have the same characteristics:
13 (i) a median age of 59-63 years and a low frequency of the low-risk cytogenetic abnormalities t(8;21), inv (16) or t(15;17) (o7% of patients); (ii) a minority of patients (15-20%) with secondary AML; (iii) a minor subset with AML relapse (7-9%) and (iv) 30-40% of patients have genetic FLT3 abnormalities. 13 Leukemic peripheral blood mononuclear cells were isolated by density gradient separation (Lymphoprep; Axis-Shield, Oslo, Norway; specific density 1.077) and cells were stored in liquid nitrogen. 14 The percentage of leukemic blasts among peripheral blood mononuclear cells exceeded 95% for all the patients. 14 
Serum samples
Samples were derived from 48 consecutive patients with untreated AML (23 females, 25 males; median age 57 years; range 28-78 years), including patients without high peripheral blood blast counts. The control group consisted of 21 healthy individuals (11 females, 10 males; median age 54 years; range 35-73 years). As a comparison, we also examined serum samples from seven consecutive adult patients with untreated acute lymphoblastic leukemia. Serum samples were in addition collected from patients receiving intensive chemotherapy for AML. This treatment induces cytopenia, and so samples were taken (i) before chemotherapy (n ¼ 13), (ii) during the first 1-6 days of neutropenia (n ¼ 25), (iii) during 7-12 days of neutropenia (n ¼ 17) and (iv) after 412 days of neutropenia (n ¼ 11) from 17 different patients during 30 chemotherapy cycles (12 induction cycles and 18 consolidation cycles). The number of samples at each time point differed due to early reconstitution, new induction therapy due to regrowth of leukemia or technical reasons. Patients were usually neutropenic (absolute neutrophil counts o0.5 Â 10 9 l À1 ) 6-8 days after the start of chemotherapy. In 10 cases the patients were already neutropenic before receiving chemotherapy, and for these patients we analyzed samples collected 5-10 days and 11-16 days after treatment onset.
Polymerase chain reaction and sequence analysis of FLT3-ITD and NPM1 mutations DNA was purified from cryopreserved cells using QIAamp Blood Mini Kit (Qiagen, Hilden, Germany). Polymerase chain reaction (PCR) was carried out under standard conditions using 50-100 ng DNA and the primers HEX-labeled i11F: 5 0 -ATGTT GAACTATGCAAAGAGACATT-3 0 and e12R: 5 0 -ACAGGCA TTTTGGACAACAC-3 0 for detection of NPM1 mutations in exon 12, and FAM-labeled i13F:5 0 -GCAGAACTGCCTATTCCTAAC TG-3 0 and e15R:5 0 -ATAAGCTGTTGCGTTCATCAC-3 0 for FLT3 length mutations. The PCR products were separated on ABI prism 3100 and the mutations were detected as PCR products larger than the wild type (wt) (NPM1c ¼ þ 4 nt, FLT3-ITD ¼ þ 3-207 nt). Mutations were confirmed by sequencing using Big Dye 1.1.
Microarray and real-time quantitative PCR analysis
Synthesis of cDNA and Cy-labeled cRNA targets and hybridization of Agilent 44k microarrays (Agilent Technologies G4112A, Santa Clara, CA, USA) according to the Agilent hybridization kit protocol have been described previously. 15 Features were extracted using Agilent Microarray ScannerBundle v7.5.1 and were processed using J-Express Pro v2.7 (www.molmine.com) to filter and normalize data from each hybridization and compile gene expression profile matrix data sets. 15 Analysis was restricted to patients with normal cytogenetics and FLT3-ITDs, and Significance Analysis of Microarrays (SAM) in J-Express Pro 2.7 was used to examine the correlation of gene expression data between AML cells with (10 patients) and without (nine patients) NPM1 mutations. SAM used 400 permutations of the sample sets to estimate the false discovery rate. Real-time quantitative PCR was performed as previously described. 15 Dilution series of pooled samples were used for the generation of standard curves for each TaqMan assay including the endogenous control, glyceraldehyde-3-phosphate dehydrogenase. Samples were tested in duplicates. The SDS2.2 software was used for analysis according to the Applied Biosystems (Foster City, CA, USA) User Bulletin no. 2. The following TaqMan quantitative PCR assays were obtained from Applied Biosystems: Hs99999905_m1 (glyceraldehyde-3-phosphate dehydrogenase) and Hs00919200_m1 (Ang-1/ANGPT1).
Non-leukemic cell lines and primary BMSCs
The following nonleukemic human cell lines were cultured: 16 (i) the fibroblast cell lines HFL1 (American Type Culture Collection, ATCC, Manassas, VA, USA; ATCC no. CCL-153) and Hs27 (ATCC no. CRL-1634) and (ii) the two osteosarcoma cell lines Cal-72 (German Collection of Microorganisms and Cell Cultures, DSMZ, Braunschweig, Germany) and SJSA-1 (ATCC no. CRL-2098) with an osteoblastic phenotype. Normal human bone marrow stromal cells (BMSCs) derived from three random patients without a hematological disease were prepared as described previously. 17 Cell culture studies, cell viability assay and flow cytometric analysis Non-leukemic cell lines (10 4 cells in 1 ml medium) or primary BMSCs (1.5 Â 10 4 in 1 ml medium) were added to the lower chamber of Transwell culture plates (cat. no. 3401, 0.4 mm pore size; Corning, Costar, Cambridge, MA, USA), before AML cells (10 6 in 0.5 ml medium) were added to the upper chamber.
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Culture supernatants were harvested after 7 days. Transwell cultures of AML blasts and cell lines were grown in Stem Span SFEM (Stem Span Tech., Vancouver, BC, Canada) added 10% heat-inactivated fetal calf serum (BioWhittaker, Verviers, Belgium) and 100 mg ml À1 gentamicin, while cocultures of BMSCs and AML cells were grown in EGM-2MV (Cambrex, Clonetics, Walkersville, MA, USA).
Acute myelogenous leukemia supernatants were also collected from AML cultures grown alone for 48 h in Stem Span medium (2 Â 10 6 cells in 2 ml) in 24-well culture plates (Nunclon, Roskilde, Denmark). All cell cultures were incubated at 37 1C in a humidified 5% CO 2 incubator. Cytokine levels in the supernatants were analyzed with enzyme-linked immunosorbent assays (Quantikine human kits; R&D Systems, Minneapolis, MN, USA). Minimal detectable levels were as follows: Ang-1, 3.5 pg ml À1 ; Ang-2, 8.3 pg ml À1 ; vascular endothelial growth factor (VEGF), 5 pg ml
À1
; hepatocyte growth factor (HGF), 40 pg ml À1 ; CXCL1, 10 pg ml À1 ; CXCL9, 3.8 pg ml À1 ; CXCL10, 1.7 pg ml À1 ; CXCL11, 13.9 pg ml À1 ; CCL2 5.0 pg ml À1 ; CCL3, 10 pg ml À1 and CCL4, 4.0 pg ml À1 . The 3 H-labeled thymidine incorporation assay was used to evaluate AML cell proliferation in (i) Transwell cultures (see above) or (ii) cultures prepared in 96-well plates (5 Â 10 4 cells in 200 ml medium). 13 Endothelial cell proliferation in Transwell cultures was assayed by the similar assay (8 Â 10 3 cells per well, 7 days of incubation). Tie2 neutralization was performed using 5 mg ml À1 goat anti-human Tie2 antibody, and control cultures were prepared with a corresponding control antibody (R&D Systems). Spontaneous in vitro apoptosis of AML cells cultured for 72 h in Stem Span medium was assayed by flow cytometry.
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Tie2 expression was detected by staining with phycoerythrin-conjugated anti-Tie2 monoclonal antibody and compared with isotypic controls (R&D Systems).
Migration assay
Pulmonary microvascular endothelial cells, 17 (5 Â 10 4 cells) suspended in 100 ml EGM-2MV medium were seeded onto cell culture inserts (8 mm pore size; BD Falcon, Franklin Lakes, NJ, USA) in 24-well plates. Various concentrations of AML supernatants were added to the lower well. After 6 h of incubation, cells were fixed and stained with Hoechst 33342 and the number of migrated cells counted with ImageJ software.
Presentation of the data
All statistical analyses were performed using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). Differences and correlations were regarded as statistically significant when Po0.05.
Results
NPM1 and FLT3-ITD mutations
Nucleophosmin mutations were found in 17 out of 62 patients (27% of patients examined) and associated with normal karyotypes and low (o10%) expression of CD34 on AML cells (w 2 -test, P ¼ 0.0001 for both), and also FAB subtypes M4/M5 (w 2 -test, M4/M5 versus other FAB subtypes, P ¼ 0.001). As the prognostic impact of NPM1 mutations differs between patients with and without FLT3-ITDs, [2] [3] [4] [5] [6] we compared the ITD sequences for 34 patients with and without NPM1 mutations (Table 1) . However, the FLT3-ITDs did not differ with regard to loss of wt, localization or length of the inserted fragment, number of tyrosine residues or new proline residues.
AML cytokine release by patients with and without NPM1 mutations
The constitutive release of Ang-1 and Ang-2 was determined in AML cell culture supernatants. The levels of both mediators varied considerably between patients (Figure 1a ). Detectable Ang-1 was observed for 62 out of 91 patients (median 94.5 pg ml À1 ; range o3.5-2172.1 pg ml À1 ), whereas Ang-2 release was observed for 23 patients (median o8.3 pg ml À1 ; range o8.3-3000 pg ml À1 ). The majority of patients (22/23) with release of Ang-2 also showed release of Ang-1 (P ¼ 0.001, Fisher's exact test), and the Ang-2 levels were then significantly lower than the corresponding Ang-1 levels (Wilcoxon's test, P ¼ 0.01). We found no correlation between Ang-1/Ang-2 and FAB-classification, cytogenetics or FLT3 mutations (data not shown).
Of the 60 patients examined for expression of Tie2 on AML cells, 23 patients expressed 410% Tie2 (range 0-62%, mean 12%). We found no correlation between Tie2 expression and Ang-1/Ang-2 levels, between Tie2/Ang-1/Ang-2 and spontaneous in vitro apoptosis (19 patients examined) or Tie2/Ang-1/ Ang-2 and in vitro AML cell proliferation (72 patients examined).
We compared the constitutive release of Ang1, Ang2, VEGF, HGF and angioregulatory chemokines (CXCL1, CXCL8-11, CCL2-4) by AML cells with the NPM1 mutational status for a subset of AML patients. First, when comparing NPM1 wt and mutated patients, we observed an association between Ang-1 levels and NPM1 mutations (Figure 1b ; Fisher's Exact Test, P ¼ 0.003). We also found increased levels of CXCL8 (MannWhitney U-test, P ¼ 0.003), CCL3 (P ¼ 0.009), CCL4 (P ¼ 0.044) and CXCL1 (P ¼ 0.054) for patients with NPM1 mutations (Figure 1d ; data shown for CXCL8), but the levels of HGF were decreased (Figure 1c , Mann-Whitney U-test, P ¼ 0.006). Similar results for HGF were also observed for an independent group of 38 patients (data not shown). CCL2 and CXCL9-11 levels did not differ (data not shown). When comparing cytokine median levels for NPM1-mutated patients with and without FLT3-ITDs, neither the levels of Ang-1 (median 133.1 versus 154.6 pg ml À1 ), CXCL8 (median 32215 versus 33185 pg ml À1 ), HGF (median 42.7 versus 48.5 pg ml À1 ), nor any other cytokine (data not shown) differed between the two groups.
Ang-1 mRNA levels are increased for AML cells with NPM1 mutations
To identify genes that are possibly involved in leukemogenesis and show altered expression due to NPM1 mutations, we compared the global gene expression profile for 19 patients with normal cytogenetics, FLT3-ITDs and either with or without NPM1 mutations. This approach was chosen to reduce the heterogeneity within the study population and to investigate a patient subset where NPM1 mutations are likely to be important in leukemogenesis. SAM identified 1807 genes that changed at least 1.4-to 7-fold, with a false discovery rate (%) less than 5. Of these, 72 genes exhibited a false discovery rate below 0. AML samples with NPM1 mutations showed a 2.9-and 3.4-fold overexpression (false discovery rate o5%) of Ang-1 transcript 2 and transcript 1, respectively, compared with NPM1 wt samples. The Ang-1 microarray results were validated by using real-time quantitative PCR for 15 unselected patients (Spearman's , r ¼ 0.786, P ¼ 0.0001). A correlation was also observed between microarray results and Ang-1 protein levels in AML cultures (Spearman's , r ¼ 0.716, P ¼ 0.004).
Ang-1 protein levels are increased during coculture of primary AML cells and BMSCs , range 56.7-1798.5 pg ml À1 ) and for the AML control cultures (median 124.7 pg ml À1 , range 0-1658.2 pg ml À1 ). Also, the levels of Ang-1 in AML cultures showed a positive correlation with levels in corresponding cocultures (Spearman's , r ¼ 0.822, P ¼ 0.0001). These results were reproduced for a subset of patients in cocultures with BMSCs derived from two additional cell donors (data not shown).
In addition we examined two fibroblast cell lines (Hs27 and HFL1) and the osteosarcoma cell lines (Cal-72 and SJSA-1) in the Transwell coculture assay (Figure 2a ). All stromal cell lines released detectable Ang-1 levels (range 66-408 pg ml À1 for the various cell lines). Supra-additive levels of Ang-1 were detected in the majority of cocultures when testing the fibroblast cell lines Hs27 (19/25 patients, P ¼ 0.004) and HFL1 (21/30, P ¼ 0.063, not significant), and the Cal-72 osteosarcoma cells (20/30, P ¼ 0.002), whereas only a minority of SJSA-1 cocultures had supra-additive levels. Constitutive Ang-2 levels by primary AML cells were detected for 11 out of 30 patients (median 41.1 pg ml À1 , range 9.8-561.4 pg ml À1 ), whereas primary BMSCs did not release detectable Ang-2, and supra-additive levels were observed for only four patients (data not shown). Fibroblast/osteosarcoma cell lines cultured alone released low (o8 pg ml À1 ) or undetectable levels of Ang-2, except for SJSA-1 that released high levels of Ang-2 (42000 pg ml À1 ). Still, supraadditive Ang-2 levels were uncommon in cocultures for all cell lines (data not shown). We conclude that different types of stromal cells can alter local Ang-1 levels in the presence of primary AML cells.
We examined the effect of blocking Ang/Tie2 interactions on AML cell proliferation during coculture with endothelial cells. Detectable proliferation (41000 c.p.m.) was observed for seven of the eight patients tested, and receptor neutralization decreased AML cell proliferation (Figure 1e ; Wilcoxon's test, P ¼ 0.018). The decrease of proliferation did not relate to NPM1 mutational status or the AML cell expression level of Ang-1 protein or Tie2. 
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In an endothelial cell migration assay, the presence of AML supernatants increased endothelial cell migration by more than 50% for only two of 15 patients (patients with detectable Ang-1 levels examined), and blocking of the Tie2 receptor did not alter endothelial cell migration (data not shown). Also, proliferation of endothelial cells was not altered by Tie2 receptor blocking (data not shown).
Ang-2 serum levels are increased in patients with untreated AML Serum levels of Ang-2 in untreated AML patients were significantly increased (median 4221 pg ml À1 , range 1873-31 499 pg ml
À1
) compared with healthy controls (median 1124 pg ml
, range 653-2772 pg ml À1 ) (Figure 2b , MannWhitney U-test, P ¼ 0.0001). Similarly, serum levels of Ang-2 were also significantly increased in untreated acute lymphoblastic leukemia patients (n ¼ 7, median 3367 pg ml À1 , range 1523-5845 pg ml À1 ) compared with healthy controls (data not shown, Mann-Whitney U-test, P ¼ 0.0001). There was no significant difference between levels of Ang-2 in serum AML and acute lymphoblastic leukemia samples. Finally, we examined Ang-2 serum levels for 17 AML patients before and during intensive chemotherapy. High levels were detected before chemotherapy compared with the healthy controls, and no significant difference was seen between induction and consolidation treatment cycles. Ang-2 serum levels were still significantly higher than for healthy controls even when tested after 1-6, 7-12 and more than 12 days of therapy-induced cytopenia (Figure 2c , Po0.002 for all comparisons).
Discussion
Several observations suggest that angiogenesis is important for leukemogenesis and chemosensitivity in AML. 10 Increased vessel density is detected in the leukemic bone marrow, 10, 19 and the expression of angiogenic mediators such as VEGF, HGF and Ang-2 seems to have a prognostic impact after intensive AML chemotherapy. 10, [20] [21] [22] [23] [24] These observations suggest that angioregulatory mediators should be investigated as possible targets in AML therapy. Our study is the first to quantify differences in Ang-1/Ang-2 protein release and also determine serum levels of Ang-2 in patients undergoing chemotherapy.
We investigated the gene expression of Ang-1 and quantified the release of Ang-1 and Ang-2 by primary AML blasts cultured under highly standardized and well-characterized in vitro conditions. 14, 18 The observed relationship between NPM1 mutations and Ang-1 levels both at the gene expression and protein levels, suggests that angiopoietin associated angioregulation is important especially for patients with NPM1 mutations. Increased protein release of proangiogenic CXCL8 was also associated with NPM1 mutations, and a similar increase in CCL3, CCL4 and CXCL1 levels is expected because the constitutive release by primary AML cells of these chemokines is correlated with CXCL8 release. 25 In addition, we found a decrease in HGF protein released by AML cells derived from patients with NPM1 mutations. HGF is a proangiogenic mediator, and high systemic levels at diagnosis is associated with a poor prognosis in AML. 21 The decreased HGF levels are possibly mediated by upregulation of the Jagged 1 (JAG1) gene that inhibits HGF expression, 26 and is upregulated in AML patients with NPM1 mutations. 8 Primary AML cells were cultured with various stromal cells that support AML cell proliferation.
14, 18 We detected supraadditive levels of Ang-1 in cocultures of primary AML cells together with the two fibroblast cell lines and the osteosarcoma cell line Cal-72. The high Ang-1 levels in cocultures are mainly due to AML cells, because the levels found in cocultures correlated significantly with levels in AML cell cultures. Although stromal cells usually increase the proliferation of AML cells, 14, 18 increased levels of Ang-1 in cocultures cannot be explained merely by the altered proliferation; as increased proliferation was not always associated with increased release of Ang-1 and vice versa (data not shown). Taken together, our results demonstrate that the bidirectional crosstalk between AML cells and neighboring nonleukemic cells will modulate local Ang-1 and Ang-2 levels, but the capability of constitutive release by the AML cells still has a major influence.
Our results demonstrate that primary AML cells generally show constitutive release of Ang-1 protein, only some patients show detectable Ang-2 release and Tie2 expression on AML cells varies between patients. The Ang-1/Tie2 loop can be involved in the regulation of AML cell apoptosis and survival. 27 However, this probably applies only for certain patients, 27 because when comparing our overall results, the effect of an intact autocrine Ang-1/Tie2 loop (constitutive Ang-1 release plus Tie2 expression) did not reach a statistically significant correlation with apoptosis or proliferation.
Several studies have shown that Ang-1 does not alter the proliferation of endothelial cells 11 and has chemotactic properties at high concentrations. 28 Our results support these data as endothelial cell proliferation was unaltered after blocking Ang/ Tie2 interactions. When we studied endothelial cell migration in vitro, AML supernatants did not affect cell migration for most patients tested. These results are similar to the observations previously described by de Bont et al. 19 In our experimental models, the chemotactic proteins Ang-1 and VEGF are released by AML cells at levels that are most likely too low to induce a chemotactic response of endothelial cells towards AML supernatants. 28 Also, previous studies have shown that Ang-1 levels and microvessel density are not correlated in AML bone marrow. 23, 29 Rather than having a direct effect on endothelial cells, our neutralization experiments suggest that Ang-1 is involved in the crosstalk between AML and endothelial cells thereby causing increased AML cell proliferation.
A recent study by Schliemann et al. 24 described that AML patients have high plasma levels of Ang-2, and high levels were associated with decreased survival after intensive chemotherapy. We also found increased Ang-2 levels when investigating a group of unselected patients. This increase is not specific for AML, as we observed high levels also in acute lymphoblastic leukemia patients. Furthermore, our observation that the high Ang-2 levels persist during chemotherapy-induced cytopenia Figure 2 The angiopoietin system in AML: Ang-1 release during coculture of AML and stromal cells and variations in Ang-2 serum levels. (a) Ang-1 ratio in supernatants harvested from Transwell cocultures of primary AML cells and nonleukemic stromal cells after 7 days of culture. Cocultures with normal stromal cells (BMSCs), fibroblasts (Hs27) and osteoblastic (Cal-72) cells showed a significant increase (Po0.05) of the Ang-1 ratio; defined as the Ang-1 concentrations in cocultures relative to the summarized concentrations in control cultures (containing the corresponding AML cells alone and stromal cells alone). The lower limit for a supra-additive effect is shown as the dotted line at ratio equal to 1 (ÀÀ). (b) Ang-2 serum levels were measured by enzyme-linked immunosorbent assay in consecutively collected serum samples from 48 untreated AML patients and 21 healthy controls; the median level is indicated (F). (c) Serum Ang-2 levels in patients with chemotherapy-induced neutropenia. Ang-2 levels were determined (i) at the onset of therapy, (ii) during 1-6 days of neutropenia, (iii) during 7-12 days of neutropenia and (iv) more than 12 days after the development of chemotherapyinduced neutropenia. The results are presented as the median (F), 25-75 percentiles (box) and variation range (whiskers). AML, acute myelogenous leukemia; BMSC, bone marrow stromal cell. and later during consolidation therapy suggests that the increased levels are caused by release from nonleukemic cells in the bone marrow or in distant organs and not from the AML cells.
In summary, our present results suggest an association between NPM1 mutations and the release of angioregulatory mediators by human AML cells. This association warrants further investigation of the angiopoietin system as a possible therapeutic target especially in this subset of AML patients.
